Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Hysterectomy, Benign Uterine Diseases
Interventions: benign hysterectomy; Device
Lead sponsor: Distalmotion SA; Industry
Eligibility: 22 Years and older · Female only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Wichita, Kansas • Houston, Texas

Conditions: Cachexia
Interventions: (non-radioactive) Oral deuterated 3-methylhistidine (D-3MH); Biological
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Parkinson Disease
Interventions: Vibrotactile coordinated reset; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Non Small Cell Lung Cancer
Interventions: Mediastinoscopy/thoracoscopy, EBUS/EUS; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Jacksonville, Florida • Rochester, Minnesota • Charleston, South Carolina

Conditions: Urologic Diseases
Interventions: PEAL surgery; Procedure
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Temperature Monitoring
Interventions: Temple Touch Pro; Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 0 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Bladder Cancer
Interventions: Intravenous ascorbic acid/vitamin C; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Iowa City, Iowa • Kansas City, Kansas

Conditions: Metastatic Breast Cancer, Leptomeningeal Disease
Interventions: High-dose Methotrexate (8 gm/m2; HD-MTX); Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 3
States / cities: Baltimore, Maryland • St Louis, Missouri • Winston-Salem, North Carolina

Conditions: Cancer
Interventions: counseling intervention, educational intervention, psychosocial assessment and care, quality-of-life assessment; Other · Procedure
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 2
States / cities: Lebanon, New Hampshire • White River Junction, Vermont

Conditions: Stroke
Interventions: Transcranial Direct Current Stimulation (tDCS), Placebo sham; Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Triple Negative Breast Cancer
Interventions: Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 188
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 158 more

Conditions: Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
Interventions: Pembrolizumab, Sacituzumab Govitecan; Drug
Lead sponsor: Ana C Garrido-Castro, MD; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 8
States / cities: Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 5 more

Conditions: Non-muscle-invasive Bladder Cancer
Interventions: PLZ4-coated paclitaxel-loaded micelles (PPM); Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Heart Failure, Heart Transplantation
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: Axillary Reverse Mapping; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Iron Overload, Hemosiderosis
Interventions: Non-contrast MRI; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 10 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Muscle-Invasive Bladder Carcinoma, Bladder Cancer Stage II, Bladder Cancer Stage III, Bladder Cancer Stage IV
Interventions: Surveys; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Cerebral Palsy (CP)
Interventions: Soterix 1x1 tDCS LTE Stimulator Device Model 1401; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 8 Years to 21 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hemophilia A
Interventions: PEGylated Recombinant factor VIII (rFVIII); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: Gainesville, Florida • Peoria, Illinois • Louisville, Kentucky + 5 more

Conditions: Hemophilia A
Interventions: Antihemophilic factor, recombinant, manufactured protein-free; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 5 Years and older · Male only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 10
States / cities: Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 7 more

Conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptom
Interventions: Rezum System, Rigid Cystoscopy; Device · Procedure
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 15
States / cities: Tucson, Arizona • Denver, Colorado • Aventura, Florida + 12 more

Conditions: Bladder Cancer, Urinary Bladder Neoplasms
Interventions: MK-3120; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Bakersfield, California • New Brunswick, New Jersey • Myrtle Beach, South Carolina + 1 more

Conditions: Lumbar Spinal Stenosis
Interventions: MILD® (Minimally Invasive Lumbar Decompression), Epidural Steroid Injection; Device · Drug
Lead sponsor: Coastal Orthopedics & Sports Medicine; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Bradenton, Florida

Conditions: Lumbar Spinal Stenosis
Interventions: Percutaneous Lumbar Decompression, Epidural Steroid Injection; Procedure · Drug
Lead sponsor: Vertos Medical, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 27
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Aptos, California + 24 more

Search by objective public record fields.

Robotic Minimally Invasive Benign Hysterectomy Post-market Clinical Study With the DEXTER Robotic System

Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II

Vibrotactile Coordinated Reset for the Treatment of Advanced Parkinson's Disease

Study Comparing EBUS & EUS to Mediastinoscopy in Staging and Detection of Lung Cancer

Percutaneous Externally-Assembled Laparoscopic Urologic Surgery

Non-invasive Temperature Monitoring in Pediatric Intensive Care Patients Requiring Targeted Temperature Management: Evaluation of Temple Touch Pro

Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients

Robots Paired With tDCS in Stroke Recovery

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

A Phase I Intravesical PPM Therapy for NMIBC

Non-invasive Evaluation of Heart Transplant Rejection- Pilot Study

Axillary Reverse Mapping for Invasive Carcinoma of the Breast

Non-invasive Quantification of Liver Iron With MRI

Addressing Barriers to Palliative Care Use in Bladder Cancer

Pediatric Teleneuromodulation

Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures

Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery

Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)

A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

Study of Epidural Steroid Injection (ESI) Versus Minimally Invasive Lumbar Decompression (Mild®) in Patients With Symptomatic Lumbar Central Canal Stenosis

MiDAS III (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study